Akero Therapeutics (AKRO) Stock Price, News & Analysis

Written before these shares stopped trading.

Akero Therapeutics, Inc. (Nasdaq: AKRO) is a clinical-stage biopharmaceutical company focused on developing treatments for serious metabolic diseases marked by high unmet medical need, with a primary emphasis on metabolic dysfunction-associated steatohepatitis (MASH). According to company disclosures, Akero’s work centers on patients across the spectrum of MASH, including those with pre-cirrhotic fibrosis and compensated cirrhosis, conditions associated with a high risk of liver failure, liver cancer and death. The company is headquartered in South San Francisco, California and its common stock is listed on The Nasdaq Global Select Market under the symbol AKRO.

Akero’s lead product candidate is efruxifermin (EFX), which the company describes as its primary development program for MASH. EFX is being evaluated in multiple late-stage clinical studies and has been observed in Phase 2 trials to reverse fibrosis, including compensated cirrhosis due to MASH, resolve MASH, reduce non-invasive markers of fibrosis and liver injury, and improve insulin sensitivity and lipoprotein profile. EFX is engineered to mimic the biological activity profile of native FGF21 and is designed for once-weekly subcutaneous dosing, and has been generally well-tolerated in clinical trials to date, based on the company’s reported data.

Clinical development strategy

Akero’s development strategy for EFX is organized around the global Phase 3 SYNCHRONY program, which the company reports is comprised of three randomized, placebo-controlled trials enrolling approximately 3,500 participants. These trials are designed to evaluate the efficacy and safety of EFX in patients with both pre-cirrhotic (F2–F3 fibrosis) MASH and compensated cirrhosis (F4) due to MASH, as well as in a broader, non-invasively diagnosed population with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease).

• SYNCHRONY Histology evaluates EFX in patients with biopsy-confirmed pre-cirrhotic (F2–F3 fibrosis) MASH. The study includes weekly injections of 28 mg EFX, 50 mg EFX, or placebo and assesses histologic endpoints such as ≥1-stage fibrosis improvement and MASH resolution.
• SYNCHRONY Outcomes evaluates 50 mg EFX in patients with compensated cirrhosis (F4) due to MASH, focusing on both histologic improvement (≥1-stage fibrosis improvement with no worsening of steatohepatitis) and protocol-specified clinical outcomes events over long-term follow-up.
• SYNCHRONY Real-World assesses the safety and tolerability of 50 mg EFX in patients with non-invasively diagnosed MASH or MASLD (F1–F4), reflecting a broader clinical setting outside strictly biopsy-confirmed cohorts.

These Phase 3 studies build on two Phase 2b trials, HARMONY in pre-cirrhotic (F2–F3) MASH and SYMMETRY in compensated cirrhosis (F4) due to MASH. Akero has reported that in multiple Phase 2 studies, EFX has been observed to reverse fibrosis, resolve MASH, and improve non-invasive markers of liver injury and fibrosis, as well as broader metabolic parameters.

Key clinical data programs

The Phase 2b HARMONY trial was a multicenter, randomized, double-blind, placebo-controlled study in adults with biopsy-confirmed MASH and fibrosis stage 2 or 3. Over up to 96 weeks of once-weekly subcutaneous dosing of 28 mg or 50 mg EFX or placebo, the primary efficacy endpoint was the proportion of participants with ≥1-stage fibrosis improvement without worsening of MASH. Company reports describe that continued treatment with EFX from 24 to 96 weeks led to more participants exhibiting improvements in fibrosis and MASH, with near complete reversal of disease in a subset of participants receiving the 50 mg dose. Akero has also highlighted improvements in markers of liver injury, whole-body metabolic health, and non-invasive measures such as liver stiffness and ELF score.

The Phase 2b SYMMETRY study evaluated EFX in patients with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, due to MASH. Akero has reported statistically significant reversal of compensated cirrhosis following 96 weeks of treatment with 50 mg EFX, including ≥1-stage improvement in fibrosis without worsening of MASH in a meaningful proportion of patients compared with placebo. The company notes that SYMMETRY data have been published in the New England Journal of Medicine and presented at major liver disease congresses, and that additional analyses have suggested benefits across key subgroups, including patients with cryptogenic cirrhosis attributed to MASH and those with type 2 diabetes at baseline.

Across both HARMONY and SYMMETRY, Akero has incorporated advanced tools such as AI-based digital pathology (including qFibrosis and other platforms) alongside conventional histopathology and non-invasive tests (e.g., ELF score and liver stiffness by FibroScan). Company communications state that these analyses help distinguish treatment effects from placebo variability and corroborate the antifibrotic activity of EFX in pre-cirrhotic and cirrhotic MASH populations.

Disease focus: MASH and MASLD

Akero positions its research within the broader context of metabolic dysfunction-associated steatotic liver disease. The company describes MASH as a serious form of MASLD characterized by excess fat accumulation in the liver, cellular stress and injury, inflammation and fibrosis, which can progress to cirrhosis, liver failure, cancer and death. Company materials note that there are no approved treatments for compensated cirrhosis due to MASH and that MASH is one of the fastest growing causes of liver transplants and liver cancer in the United States and Europe. By targeting fibrosis regression and MASH resolution, Akero aims to address both liver-specific outcomes and systemic metabolic risk factors, including those linked to cardiovascular disease.

Corporate developments and ownership

Akero Therapeutics has disclosed that it entered into an Agreement and Plan of Merger with Novo Nordisk A/S and a wholly owned subsidiary of Novo Nordisk. Under this agreement, Merger Sub will merge with and into Akero, with Akero surviving as a wholly owned subsidiary of Novo Nordisk, subject to customary closing conditions, regulatory approvals and stockholder approval. At the effective time of the merger, each outstanding share of Akero common stock (other than specified excluded or dissenting shares) is expected to be converted into cash consideration and a contractual contingent value right tied to a specified U.S. regulatory milestone for efruxifermin in compensated cirrhosis due to MASH, as described in the company’s Form 8-K and related disclosures.

Until completion of the merger, Akero continues to operate as a publicly traded company with its common stock registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Select Market. The company has also reported the termination of a prior loan agreement following voluntary prepayment of all outstanding obligations, reflecting changes in its capital structure as it advances late-stage clinical development.

Business model and sector classification

Within the broader manufacturing sector, Akero is classified under pharmaceutical preparation manufacturing, reflecting its focus on the research and development of drug candidates rather than commercial-scale production at this stage. As a clinical-stage company, Akero’s activities and reported expenses are concentrated in research and development, including large global Phase 3 programs, manufacturing of clinical supplies for potential marketing applications, and general and administrative functions associated with operating as a public company.